<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02211352</url>
  </required_header>
  <id_info>
    <org_study_id>GS302-100</org_study_id>
    <secondary_id>GS302-100</secondary_id>
    <nct_id>NCT02211352</nct_id>
  </id_info>
  <brief_title>Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension</brief_title>
  <acronym>KRGCBP</acronym>
  <official_title>Randomized Control Clinical Trial for Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daegu Catholic University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Korean Society of Ginseng</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Daegu Catholic University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine Korean red ginseng (KRG)treatment could decrease
      central blood pressure in subjects with hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with hypertension who were treated with antihypertensive agents were randomly
      assigned to an active (KRG 2 g/day) or a placebo treatment group in a double-blind cross over
      manner.

      Participants were not allowed to change their antihypertensive medications except safety
      issue. Brachial systolic BP (SBP), diastolic BP (DBP), Central SBP and DBP will measured at
      baseline,at 2 and 4 months.

      Efficacy and safety data will be monitored by Daegu Catholic University Medical Center
      Institutional Review Board and reported to the Korean Ginseng Society.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>central blood pressure change after treatment of Korea Red Ginseng</measure>
    <time_frame>baseline, 8 weeks and 16 weeks after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>brachial systolic and diastolic blood pressure</measure>
    <time_frame>baseline, 8 week, 16 week.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augumentation index</measure>
    <time_frame>baseline, 8 week, 16 week.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESR(erythrocyte sedmentation rate)</measure>
    <time_frame>baseline, 8 week, 16 week.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP(C-reactive protein)</measure>
    <time_frame>baseline, 8 week, 16 week.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>AST(Aspartate Aminotransferase)</measure>
    <time_frame>baseline, 8 week, 16 week</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>baseline, 8 week, 16 week</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>fasting blood glucose</measure>
    <time_frame>baseline, 8 week, 16 week</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hb A1c(Hemoglobin A1c)</measure>
    <time_frame>baseline, 8 week, 16 week</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Active(Korean Red Ginseng) first group:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Korean Red Ginseng Capsules 2g,daily, 8 week and than crossover to placebo capsules(2g), daily 8week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo Capsules(2g),daily, 8 week and than crossover to Korean Red Ginseng capsules(2g), daily 8week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Korean Red Ginseng Capsules</intervention_name>
    <description>Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week</description>
    <arm_group_label>Active(Korean Red Ginseng) first group:</arm_group_label>
    <other_name>Korean Red Ginseng (KRG) Capsule was manufactured</other_name>
    <other_name>from roots of a 6-year-old Panax ginseng Meyer.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week</description>
    <arm_group_label>Placebo capsules</arm_group_label>
    <other_name>Placebo of Kerea Red Ginseng(KRG) Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Essential hypertension

          -  diastolic blood pressure 100 mmHg or less and systolic blood pressure 160 mmHg or less

        Exclusion Criteria:

          -  Secondary hypertension

          -  Serum creatinin above 1.5 mg/dL

          -  aspartate aminotransferase(AST) and alanine aminotransferaseALT above two times upper
             normal limits

          -  Uncontrolled diabetes (Hb A1c &lt; 9%)

          -  Acute myocardial infarction or coronary artery disease intervention within six months

          -  Moderate to severe congestive heart failure

          -  HIV positive

          -  Immunocompromized host

          -  Allergy to Korean red ginseng

          -  Pregnancy or plan to pregnancy

          -  Alcohol or drug abuse

          -  Attend to other clinical trial within 12 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Bae Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daegu Catholic University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2013</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2014</study_first_posted>
  <last_update_submitted>August 6, 2014</last_update_submitted>
  <last_update_submitted_qc>August 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Daegu Catholic University Medical Center</investigator_affiliation>
    <investigator_full_name>Jin Bae Lee</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>blood pressure, ginseng</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

